On Feb. 17, Baxter updated its progress at its North Cove facility. The announcement said that all 10 of the site’s manufacturing lines had restarted,
Baxter noted that it has now returned to pre-hurricane production levels. “While we continue to increase allocation levels across key impacted product groups, allocations remain necessary, and we will continue to provide related updates for our customers directly,” the announcement said.
Baxter commented that the progress was made possible by the dedication and resilience of the North Cove and broader Baxter teams, working in coordination with FDA.
Janette Wider is Editor-in-Chief for Healthcare Purchasing News.
